+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Thalassemia Drugs Market 2018-2022 - Product Image

Global Thalassemia Drugs Market 2018-2022

  • ID: 4618176
  • Report
  • August 2018
  • Region: Global
  • 109 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • MORE
About Thalassemia

Thalassemia is an inherited blood disorder that predominantly affects the iron levels in the red blood cells. There are two types of drugs for the treatment of thalassemia, alpha thalassemia drugs and beta thalassemia drugs.

The analysts forecast the Global Thalassemia Drugs Market to grow at a CAGR of 9.9% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the thalassemia drugs market. To calculate the market size, the report considers the revenue generated from the retail sales of alpha thalassemia drugs and beta thalassemia drugs across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, thalassemia drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Market drivers
  • Increasing prevalence of thalassemia
  • For a full, detailed list, view the full report
Market challenges
  • High expense of treatment
  • For a full, detailed list, view the full report
Market trends
  • Rising disease awareness programs
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the Key vendors in this market space?
  • What are the market opportunities and threats faced by the Key vendors?
  • What are the strengths and weaknesses of the Key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY CATEGORY
  • Segmentation by category
  • Comparison by category
  • Alpha thalassemia drugs – Market size and forecast 2017-2022
  • Beta thalassemia drugs – Market size and forecast 2017-2022
  • Market opportunity by category
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas – Market size and forecast 2017-2022
  • EMEA – Market size and forecast 2017-2022
  • APAC – Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Rising disease awareness programs
  • Rising scope for gene therapy
  • Increasing pharmaceutical R&D spending
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global thalassemia drugs market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global thalassemia drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global thalassemia drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trial candidates of thalassemia
Exhibit 20: Global thalassemia drugs market – Market share by category 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Global alpha thalassemia drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global alpha thalassemia drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global beta thalassemia drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global beta thalassemia drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by category
Exhibit 27: Customer landscape
Exhibit 28: Global thalassemia drugs market – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: ApoPharma – Overview
Exhibit 47: ApoPharma – Business segments
Exhibit 48: ApoPharma – Organizational developments
Exhibit 49: ApoPharma – Geographic focus
Exhibit 50: ApoPharma – Segment focus
Exhibit 51: ApoPharma – Key offerings
Exhibit 52: ApoPharma – Key customers
Exhibit 53: Fresenius Kabi – Overview
Exhibit 54: Fresenius Kabi – Business segments
Exhibit 55: Fresenius Kabi – Organizational developments
Exhibit 56: Fresenius Kabi – Geographic focus
Exhibit 57: Fresenius Kabi – Segment focus
Exhibit 58: Fresenius Kabi – Key offerings
Exhibit 59: Fresenius Kabi – Key customers
Exhibit 60: Novartis – Overview
Exhibit 61: Novartis – Business segments
Exhibit 62: Novartis – Organizational developments
Exhibit 63: Novartis – Geographic focus
Exhibit 64: Novartis – Segment focus
Exhibit 65: Novartis – Key offerings
Exhibit 66: Novartis – Key customers
Exhibit 67: Pfizer – Overview
Exhibit 68: Pfizer – Business segments
Exhibit 69: Pfizer – Organizational developments
Exhibit 70: Pfizer – Geographic focus
Exhibit 71: Pfizer – Segment focus
Exhibit 72: Pfizer – Key offerings
Exhibit 73: Pfizer – Key customers
Exhibit 74: Teva Pharmaceutical Industries – Overview
Exhibit 75: Teva Pharmaceutical Industries – Business segments
Exhibit 76: Teva Pharmaceutical Industries – Organizational developments
Exhibit 77: Teva Pharmaceutical Industries – Geographic focus
Exhibit 78: Teva Pharmaceutical Industries – Segment focus
Exhibit 79: Teva Pharmaceutical Industries – Key offerings
Exhibit 80: Teva Pharmaceutical Industries – Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • MORE
New Report Released: - Global Thalassemia Drugs Market 2018-2022

The author of the report recognizes the following companies as the key players in the global thalassemia drugs market: ApoPharma, Fresenius Kabi, Novartis, Pfizer, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rising disease awareness programs. Thalassemia is increasing every year, as there is no cure for the disease, it is growing rapidly in South Asian countries.”

According to the report, one driver influencing this market is the increasing prevalence of thalassemia. Thalassemia is an emerging health concern across the globe, and South Asia is a major hub for hemoglobinopathies.

Further, the report states that one challenge affecting this market is the high expense of treatment. Thalassemia is a blood disorder and can be treated by frequent blood transfusions which drives high the cost of treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • ApoPharma
  • Fresenius Kabi
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
Adroll
adroll